Generation Bio (NASDAQ:GBIO) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Generation Bio (NASDAQ:GBIO) posted its earnings results on Wednesday. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05, reports. Generation Bio had a negative return on equity of 92.86% and a negative net margin of 1,202.56%. The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $2.16 million.

Generation Bio Trading Down 5.0 %

Shares of GBIO stock traded down $0.12 during trading hours on Friday, reaching $2.26. 185,589 shares of the stock were exchanged, compared to its average volume of 181,326. Generation Bio has a 12-month low of $1.02 and a 12-month high of $4.65. The firm has a market capitalization of $150.83 million, a price-to-earnings ratio of -1.00 and a beta of 2.82. The company’s 50-day moving average price is $2.41 and its 200-day moving average price is $2.74.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Generation Bio in a research report on Wednesday, October 23rd. Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a research note on Thursday.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. PFG Advisors bought a new position in shares of Generation Bio in the first quarter worth about $41,000. SG Americas Securities LLC bought a new stake in Generation Bio during the 3rd quarter valued at $42,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Generation Bio by 91.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after buying an additional 9,075 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Generation Bio during the first quarter valued at $74,000. Finally, American Century Companies Inc. raised its holdings in shares of Generation Bio by 199.3% in the second quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock valued at $90,000 after acquiring an additional 21,167 shares in the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.